|
Volumn 20, Issue 115, 2011, Pages
|
New drugs and indications in 2010: Inadequate assessment; patients at risk
[No Author Info available]
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ACETYLCYSTEINE;
ALISKIREN PLUS HYDROCHLOROTHIAZIDE;
AMLODIPINE PLUS HYDROCHLOROTHIAZIDE PLUS VALSARTAN;
ARSENIC ACID DERIVATIVE;
BECAPLERMIN;
BOTULINUM TOXIN A;
BUFEXAMAC;
CARBOCISTEINE;
CELL THERAPY AGENT;
CYTOTOXIC AGENT;
DARUNAVIR;
GEMIFLOXACIN;
HYDROCHLOROTHIAZIDE;
IMATINIB;
IXABEPILONE;
KETOPROFEN;
LOSARTAN;
MILNACIPRAN;
MONOCLONAL ANTIBODY;
NEBIVOLOL;
NEFOPAM;
OMEPRAZOLE;
OXOMEMAZINE;
PEGINTERFERON ALPHA2B PLUS RIBAVIRIN;
PREGABALIN;
PRESCRIPTION DRUG;
ROSIGLITAZONE;
SIBUTRAMINE;
TIPRANAVIR;
UNINDEXED DRUG;
DRUG;
BREAST CANCER;
CANCER PATIENT;
CARDIOVASCULAR DISEASE;
CELL THERAPY;
COUGHING;
DRUG EFFICACY;
DRUG INDICATION;
DRUG INDUSTRY;
DRUG MARKETING;
DRUG SAFETY;
DRUG SURVEILLANCE PROGRAM;
DRUG TOLERABILITY;
FIBROMYALGIA;
GASTROESOPHAGEAL REFLUX;
GASTROINTESTINAL STROMAL TUMOR;
HEALTH CARE QUALITY;
HEARTBURN;
HELICOBACTER INFECTION;
HEMATOLOGIC DISEASE;
HEPATITIS C;
HUMAN;
HUMAN IMMUNODEFICIENCY VIRUS INFECTION;
HYPERTENSION;
INFECTION;
LIMBIC SPASTICITY;
NEOPLASM;
NEUROPATHY;
PAIN;
PRESCRIPTION;
PUBLIC HEALTH;
REIMBURSEMENT;
RISK ASSESSMENT;
RISK BENEFIT ANALYSIS;
RISK MANAGEMENT;
SHORT SURVEY;
SPASTICITY;
ARTICLE;
DECISION MAKING;
DRUG APPROVAL;
FRANCE;
LEGAL ASPECT;
METHODOLOGY;
POSTMARKETING SURVEILLANCE;
DECISION MAKING;
DRUG APPROVAL;
FRANCE;
HUMANS;
PHARMACEUTICAL PREPARATIONS;
PRODUCT SURVEILLANCE, POSTMARKETING;
|
EID: 79959581641
PISSN: 11677422
EISSN: None
Source Type: Journal
DOI: None Document Type: Short Survey |
Times cited : (8)
|
References (0)
|